Overview
Sanofi has re-focused on cancer and rare diseases. Immediately after Sanofi received US FDA approval for its blood disorder drug Cablivi (caplacizumab), the company announced “a rigorous pipeline prioritization review.” As a result of this overhaul Sanofi is fast-tracking 17 programs. At the same time, it is discontinuing 13 development and 25 research projects. What’s left? Find out just how many projects are in Sanofi’s R&D pipeline at this point. What does Sanofi’s enthusiasm for the rare-diseases space and its newly-formed rare blood disorder franchise mean going forward? Will Sanofi divest its animal health and/or consumer healthcare units? Find out what experts are saying.